What is the best regimen for low-risk gestational trophoblastic neoplasia? A review

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 49, Issue 8, 2004, Pages 602-616

  Osborne, Raymond ^a   Gerulath, Alan ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Gestational trophoblastic disease; Gonadotropins, chorionic, human; Pregnancy, molar; Trophoblastic cancer; Trophoblastic neoplasms

Indexed keywords

DACTINOMYCIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; NITROCAPHANE; PEMETREXED;

ALOPECIA; AMENORRHEA; BAGASHAWE REGIMEN; BIOCHEMISTRY; BOLUS INJECTION; BONE MARROW DEPRESSION; BREWER REGIMEN; CANCER CHEMOTHERAPY; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CHOICE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG RESISTANCE; EVIDENCE BASED MEDICINE; FEMALE; GASTROINTESTINAL SYMPTOM; GOOD CLINICAL PRACTICE; HUMAN; LOW DRUG DOSE; LOW RISK PATIENT; NAUSEA; PATIENT ATTITUDE; PERSISTENT TROPHOBLASTIC DISEASE; PRIORITY JOURNAL; SALVAGE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; TROPHOBLASTIC TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; DACTINOMYCIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; PROGNOSIS;

EID: 4344685950     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (64)

1. Kohorn EI: Gestational trophoblastic neoplasia and evidence-based medicine. J Reprod Med 2002;47:427-432
2. Homesley HD: Development of single-agent chemotherapy regimens for gestational trophoblastic disease. J Reprod Med 1994;39:185-192
3. Bagshawe KD: Risk and prognostic factors in trophoblastic neoplasia. Cancer 1976;38:1373-1385
4. Rose PG, Piver MS: Alternating methotrexate and dactinomycin in nonmetastatic gestational trophoblastic disease. J Surg Oncol 1989;41:148-152
5. Smith JP: Chemotherapy in gynecologic cancer. Clin Obstet Gynecol 1975;65:113-116
6. Petrilli ES, Twiggs LB, Blessing JA, et al: Single-dose actinomycin-D treatment for nonmetastatic gestational trophoblastic disease: A prospective phase II trial of the Gynecologic Oncology Group. Cancer 1987;60:2173-2176
7. Twiggs LB: Pulse actinomycin D scheduling in non-metastatic gestational trophoblastic disease: Cost-effective chemotherapy. Gynecol Oncol 1983;16:190-194
8. Schlaerth JB, Morrow CP, Nalick RH, et al: Single-dose actinomycin D in the treatment of postmolar trophoblastic disease. Gynecol Oncol 1984;19:53-56
9. Osathanondh R, Goldstein DP, Pastorfide GB: Actinomycin D as the primary agent for gestational trophoblastic disease. Cancer 1975;36:863-868
10. Song HZ, Yang XY, Xiang Y: Forty-five years′ experience of the treatment of choriocarcinoma and invasive mole. Int J Gynaecol Oncol (suppl) 1998;60:S77-S83
11. Wong LC, Choo YC, Ma HK: Primary oral etoposide therapy in gestational trophoblastic disease: An update. Cancer 1986; 58:14-17
12. Hitchins RN, Holden L, Newlands ES, et al: Single agent etoposide in gestational trophoblastic tumours: Experience at Charing Cross Hospital 1978-1987. Eur J Cancer Clin Oncol 1988;24:1041-1046
13. Elit L, Gafni A, Levine MN: Better treatments that cost more: The dilemma. Gynecol Oncol 2000;78:1-2
14. Bagshawe KD, Dent J, Newslands ES, et al: The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br J Obstet Gynaecol 1989;96:795-802
15. McNeish IA, Strickland S, Holden L, et al: Low-risk persistent gestational trophoblastic disease: Outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 2002;20:1838-1844
16. Seckl MJ: Personal communication
17. Homesley HD, Blessing JA, Schlaerth J, et al: Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease: A Gynecologic Oncology Group study. Gynecol Oncol 1990;39:305-308
18. Homesley HD, Blessing JA, Rettenmaier M, et al: Weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease. Obstet Gynecol 1988;72:413-418
19. Elit L, Covens A, Osborne R, et al: High-dose methotrexate for gestational trophoblastic disease. Gynecol Oncol 1994;54: 282-287
20. Osborne R, et al: A randomized trial of weekly parenteral methotrexate versus "pulsed" dactinomycin as primary management for low-risk gestational trophoblastic neoplasia. 1999
21. Sung HC, Wu PC, Yang HY: Reevaluation of 5-fluorouracil as a single therapeutic agent for gestational trophoblastic neoplasms. Am J Obstet Gynecol 1984;130:69-75
22. Wong LC, Choo YC, Ma HK: Use of oral VP 16-213 as primary chemotherapeutic agent in treatment of gestational trophoblastic disease. Am J Obstet Gynecol 1984;150:924-927
23. Wang Y, Jiu L, Guan Y, et al: Chemotherapy using 5-fluorouracil and nitrocaphanum in malignant trophoblastic tumor. Gynecol Oncol 1998;71:416-419
24. Su WH, Wang PH, Chang SP: Successful treatment of a persistent mole with myometrial invasion by direct injection of methotrexate. Eur J Gynaecol Oncol 2001;22:283-286
25. Berkowitz RS, Goldstein DP, Bernstein BF: Ten years′ experience with methotrexate and folinic acid rescue as primary therapy for gestational trophoblastic disease. Gynecol Oncol 1986;23:111-116
26. Ratnam SS, Teoh AS, Dawood MY: Methotrexate for prophylaxis of choriocarcinoma. Am J Obstet Gynecol 1971;111: 1021-1027
27. Barter JF, Soong SJ, Hatch KD, et al: Treatment of non-metastatic gestational trophoblastic disease with sequential intramuscular and oral methotrexate. Gynecol Oncol 1989; 33:82-84
28. Barter JF, Soong SJ, Hatch KD, et al: Treatment of non-metastatic gestational trophoblastic disease with oral methotrexate. Am J Obstet Gynecol 1987;157:1166-1168
29. Kohorn EI: Evaluation of criteria used to make the diagnosis of nonmetastatic gestational trophoblastic neoplasia. Gynecol Oncol 1993;48:139-147
30. Nixon PF: Folinic acid: Pharmacokinetics and pharmacodynamics. Clin Exp Pharm Physiol (suppl) 1979;5:35-41
31. Jolivet J, Cowan KH, Curt GA, et al: The pharmacology and clinical use of methotrexate. N Engl J Med 1983;309: 1094-1104
32. Berkowitz RS, Goldstein DP: Methotrexate with citrovorum factor rescue for nonmetastatic gestational trophoblastic neoplasms. Obstet Gynecol 1979;54:725-728
33. Wong LC, Choo YC, Ma HK: Methotrexate with citrovorum factor rescue in gestational trophoblastic disease. Am J Obstet Gynecol 1985;152:59-62
34. Kashimura Y, Kashimura M, Sugimori H, et al: Prophylactic chemotherapy for hydatidiform mole: Five to 15 years follow-up. Cancer 1986;58:624-629
35. Limpongsanurak S: Prophylactic actinomycin D for high-risk complete hydatidiform mole. J Reprod Med 2001;46: 110-116
36. Berkowitz RS, Goldstein DP, Bernstein BF: Methotrexate with citrovorum factor rescue as primary therapy for gestational trophoblastic disease. Cancer 1982;50:2024-2027
37. Berkowitz RS, Goldstein DP, Jones MA, et al: Methotrexate with citrovorum factor rescue: Reduced chemotherapy toxicity in the management of gestational trophoblastic neoplasia. Cancer 1980;45:423-426
38. Miller DS, Covens A, Bloss J: A phase 2 trial of Alimta in recurrent gestational trophoblastic neoplasia. 2003
39. Shepansky A, MacLean GD, Shepert E: Weekly methotrexate chemotherapy for non-metastatic gestational trophoblastic neoplasia. Vancouver, University Press, 1992
40. Wong LC, Ngan HY, Chang DK, et al: Methotrexate infusion in low-risk gestational trophoblastic disease. Am J Obstet Gynecol 2000;183:1579-1582
41. Major P, Dembo A: Treatment of low-risk gestational trophoblastic disease. Toronto, 1983
42. Hammond CB, Borchert LG, Tyrey L, et al: Treatment of metastatic trophoblastic disease: Good and poor prognosis. Am J Obstet Gynecol 1973;115:451-457
43. Lurain JR, Brewer JI, Torok EE, et al: Gestational trophoblastic disease: Treatment results at the Brewer Trophoblastic Disease Center. Obstet Gynecol 1982;60:354-360
44. Khoo SK, Jones IS: Medium-dose methotrexate/folinic acid regimen in the chemotherapy of gestational trophoblastic disease. Med J Aust 1980;1:317-320
45. Smith EB, Weed JC Jr, Tyrey L, et al: Treatment of non-metastatic gestational trophoblastic disease: Results of methotrexate alone versus methotrexate-folinic acid. Am J Obstet Gynecol 1982;144:88-92
46. Dorreen MS, Pennington GW, Millar DR, et al: Results of low-dose methotrexate treatment of persistent gestational trophoblastic disease in Sheffield 1980-1987. Acta Oncol 1988;27:551-556
47. Bolis G, Colombo N, Epis A, et al: Methotrexate with citrovorum factor in low-risk gestational trophoblastic tumor. Tumori 1987;73:309-313
48. Gleeson NC, Finan MA, Fiorica JV, et al: Nonmetastatic gestational trophoblastic disease: Weekly methotrexate compared with 8-day methotrexate-folinic acid. Eur J Gynaecol Oncol 1993;14:461-465
49. Gillespie AM, Kumar S, Hancock BW: Treatment of persistent trophoblastic disease later than 6 months after diagnosis of molar pregnancy. Br J Cancer 2000;82:1393-1395
50. Shigematsu T, Hirakawa T, Yahata H, et al: Identification of chemotherapeutic refractory cases based on human chorionic gonadotrophin values among patients with low-risk persistent trophoblastic disease treated with 8-day methotrexate-folinic acid. Eur J Gynaecol Oncol 2003;24:113-116
51. Moodley M, Tunikyi K, Moodley J: Gestational trophoblastic syndrome: An audit of 112 patents: A South African experience. Int J Gynecol Cancer 2003;13:234-239
52. Lurain JR, Elfstrand EP: Single agent methotrexate chemotherapy for the treatment of nonmetastatic trophoblastic tumors. Am J Obstet Gynecol 1995;172:574-579
53. Roberts JP, Lurain JR: Treatment of low-risk metastatic gestational trophoblastic tumors with single-agent chemotherapy. Am J Obstet Gynecol 1996;174:1917-1923
54. Soper JT, Clarke-Pearson DL, Berchuck A, et al: 5-Day methotrexate for women with metastatic gestational trophoblastic disease. Gynecol Oncol 1994;54:76-79
55. Li MC: Management of choriocarcinoma and related tumors of uterus and testis. Med Clin N Am 1961;45:661-675
56. Ross GT, Goldstein DP, Hertz R: Sequential use of methotrexate and actinomycin-D in the treatment of metastatic choriocarcinoma and related trophoblastic diseases in women. Am J Obstet Gynecol 1965;93:223-229
57. Ross GT, Stolbach LL, Hertz R: Actinomycin-D in the treatment of methotrexate-resistant trophoblastic disease in women. Cancer Res 1962;22:1015-1017
58. Green DM, Sallan ES, Krishan A: Actinomycin-D in childhood acute lymphatic leukemia. Cancer Treat Rep 1978;62: 829-831
59. Benjamin RS, Hall SW, Burgess MA: A pharmacokinetically based phase I-II study of single-dose actinomycin-D. Cancer Treat Rep 1976;60:289-291
60. Kohorn EI: Is lack of response to single-agent chemotherapy in gestational trophoblastic diseases associated with dose scheduling or chemotherapy resistance? Gynecol Oncol 2002;85:36-39
61. Kohorn EI: Decision making for chemotherapy administration in patients with low risk gestational trophoblastic neoplasia. Int J Gynecol Cancer 1996;6:279-285
62. Wenzel L, Berkowitz RS, Newlands E, et al: Quality of life after gestational trophoblastic disease. J Reprod Med 2002; 47:387-394
63. Bagshawe KD: Personal communication
64. Berkowitz RS, Goldstein DP, Bernstein MR: Methotrexate infusion and folinic acid in the primary therapy of non-metastatic gestational trophoblastic tumors. Gynecol Oncol 1990;36:56-59